Table 4.
Drug | Formulation | ROA | Comments | Reference |
---|---|---|---|---|
Artemether | Solid dispersions and self-emulsified solid dispersions | Oral | The solubility of artemether is enhanced. | [47] |
β-Artemether | SMEDDS | Oral | The antimalarial activity was significantly enhanced (P < 0.05) as compared with the marketed formulation (Larither®). | [48] |
β-Artemether and lumefantrine | SMEDDS | Oral | SMEDDS shows superior antimalarial activity with 100% survival as compared with the innovator (Coartem®) formulation. | [49] |
Artemether-lumefantrine | Solid SMEDDS | Oral | Optimized SMEDDS formulation at a low, medium, and high doses found to be superior in terms of reduction in parasitemia as well as mortality in comparison with the marketed tablet of equivalent dose. | [50] |